Amgen's Repatha wordt ook gebruikt door HoFH patiënten en is een stuk populairder:
"Upon its approval two years ago, Evkeeza was noted for its list price of $450,000 on average, with dosage determined by the weight of the patient. Regeneron’s sales of the drug reached just $48 million last year, climbing from $8 million in the first quarter to $15 million in the fourth.
In January of 2022, Regeneron sold rights to Evkeeza outside of the U.S. to Ultragenyx. Regeneron has another HoFH therapy, PCSK9 drug Praluent, which saw a sales drop from $170 million in 2021 to $130 million last year.
Amgen’s PCSK9 Repatha, which gained its indication for HoFH for those age 10 and up in April of 2021 and treats several other conditions, rang up sales of $1.3 billion last year, a 16% increase from 2021"